These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15086644)

  • 21. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee.
    Schnitzer TJ; Ballard IM; Constantine G; McDonald P
    Clin Ther; 1995; 17(4):602-12. PubMed ID: 8565024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
    Saag K; van der Heijde D; Fisher C; Samara A; DeTora L; Bolognese J; Sperling R; Daniels B
    Arch Fam Med; 2000; 9(10):1124-34. PubMed ID: 11115219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee.
    Makarowski W; Weaver A; Rubin B; Caldwell J; McMahon FG; Noveck RJ; Lee D; Offenberg H; Sack M; Sikes D; Trapp R; Rush S; Kuss M; Ganju J; Bocanegra TS; Ratliff JM
    Clin Ther; 1996; 18(1):114-24. PubMed ID: 8851458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis.
    Herrera JA; González M
    Am J Ther; 2003; 10(6):468-72. PubMed ID: 14624289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analgesic model for assessment of acute pain response in osteoarthritis of the knee.
    Moskowitz RW; Sunshine A; Hooper M; Olson NZ; Cawkwell GD
    Osteoarthritis Cartilage; 2006 Nov; 14(11):1111-8. PubMed ID: 16784879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
    Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.
    Bellamy N; Bensen WG; Beaulieu A; Siminovitch KA; Kraag GR; Lussier A; Ahmad S; Khanna VN; Davis P; Bell MJ
    J Rheumatol; 1995 May; 22(5):915-20. PubMed ID: 8587082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee.
    Cha HS; Koh JH; Jeon CH; Lee CK; Kim JS; Koh EM
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):539-45. PubMed ID: 11770835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Moric M; Rosenberg AG
    JAMA; 2003 Nov; 290(18):2411-8. PubMed ID: 14612477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee].
    Gijón Baños J
    Med Clin (Barc); 1997 Jun; 109(4):130-4. PubMed ID: 9289526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.
    Zacher J; Feldman D; Gerli R; Scott D; Hou SM; Uebelhart D; Rodger IW; Ozturk ZE;
    Curr Med Res Opin; 2003; 19(8):725-36. PubMed ID: 14687444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain.
    Desjardins PJ; Black PM; Daniels S; Bird SR; Fitzgerald BJ; Petruschke RA; Tershakovec A; Chang DJ
    Curr Med Res Opin; 2004 Oct; 20(10):1523-37. PubMed ID: 15462686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
    Ehrich EW; Bolognese JA; Watson DJ; Kong SX
    Am J Manag Care; 2001 Jun; 7(6):609-16. PubMed ID: 11439734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R; Rosenthal N; Wu SC; Jordan D; Kamin M;
    J Rheumatol; 2004 Jan; 31(1):150-6. PubMed ID: 14705234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
    van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
    Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rofecoxib for osteoarthritis.
    Garner SE; Fidan DD; Frankish R; Maxwell L
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD005115. PubMed ID: 15654705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
    Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
    Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.